Girihlet

Developer of a platform targeting the immune system and mitochondria to understand and fight disease

placeNew York City, New York, United States calendar_todayFounded 2014 groups2 employees language girihlet.com

Registered entities

Innovation

2 patent families (1 granted) — focus: Chemistry & metallurgy; filing pace dormant. Cited 103 times.

YearFilings
20151
20171
20181
20191

Investor mix

4 investors on record; lead investors include IndieBio.

Investor typeCountShare
Venture capital250%
Accelerator & incubator250%
Coming soon